Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heated vs. sprayed chemo: which works better for belly cancer?

NCT ID NCT07282834

Disease control Sponsor: Patrick Wagner, MD, FACS Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two methods of giving chemotherapy directly into the abdomen for people whose cancer has spread there (peritoneal carcinomatosis). One method, HIPEC, uses heated chemotherapy circulated during surgery. The other, PIPAC, delivers chemotherapy as a pressurized spray during a minimally invasive procedure. The trial will enroll 200 adults to see which approach is safer, better tolerated, and more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Mitomycin C (chemotherapy)
What this could lead to
If successful, this trial could identify which direct-to-abdomen chemotherapy method is safer and more tolerable for patients with cancer spread in the belly.
What could go wrong
This is a mid-stage trial with 200 participants, so results may not apply to all patients. Both methods involve chemotherapy side effects and surgical risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Nov 2040

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males or females age 18 to 80 years. 2. Biopsy-proven or clinically suspected peritoneal carcinomatosis 3. Receipt of at least three months of standard systemic chemotherapy prior with persistence of disease at the time of randomization 4. Not a candidate for surgical cytoreduction at the time of laparoscopy 5. Women at least 18 years of age of childbearing potential must have a negative urine/serum pregnancy test and must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study. 6. Must be able to read and understand English and consent for themselves Exclusion Criteria: 1. Patients who are eligible for definitive cytoreductive surgery at the time of enrollment 2. Laboratory abnormalities that indicate clinically significant hematologic, hepatobiliary, or renal disease: AST/SGOT \> 2.5 times the upper limit of normal ALT/SGPT \> 2.5 times the upper limit of normal Total bilirubin \> 2.5 times the upper limit of normal Hemoglobin \< 7 gm/dL White blood cell count \< 3,000/ mm3 Platelet count \< 50,000/mm3 3. Any investigational drug use within 30 days prior to enrollment. 4. Systemic therapy within 14 days prior to randomization 5. Allergy or medical contra-indication to chemotherapy utilized in this study 6. Medical contraindication to laparoscopic surgery or complex cytoreductive surgery 7. Pregnant or lactating females. 8. Subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abdominal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

digestive system cancer neoplasm Neoplasm Metastasis peritoneal carcinomatosis peritoneal neoplasm peritoneum cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abdominal cancer Abdominal cancer patients Peritoneal (metastatic) cancer Peritoneal carcinomatosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Allegheny Health Network West Penn Hospital

    RECRUITING

    Pittsburgh, Pennsylvania, 15224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.